A pooled analysis of two phase 1a/1b trials testing brigimadlin (BI 907828), a highly potent, oral MDM2–TP53 antagonist, with or without the PD-1 inhibitor ezabenlimab and the anti-LAG-3 BI 754111, revealed an encouraging ORR of 50% in patients with refractory MDM2-amplified CCA [116]. Here, TP53 is linked to cholangiocarcinoma.